Skip to main content
. 2020 Feb 19;21(4):1407. doi: 10.3390/ijms21041407

Figure 3.

Figure 3

Kaplan–Meier of SLC7A5/SLC3A2 mRNA co-expression in patients with ER+/HER2− breast cancer who received endocrine treatment only using the METABRIC cohort: (A) recurrence, (B) distant metastasis and (C) breast-cancer-specific survival. Kaplan–Meier of SLC7A5/SLC3A2 protein co-expression in patients with ER+/HER2− breast cancer who received endocrine treatment only: (D) recurrence, (E) distant metastasis and (F) breast-cancer-specific survival. (G) IHC staining of SLC7A5 and SLC3A2 from two cases of patients who were subject to endocrine therapy alone. Cell viability assay in (H) MCF7 and (J) MDA-MB-175-VII cells transfected with siRNA control or siRNA targeting SLC7A5 and SLC3A2 (si-SLC7A5/SLC3A2). Cells were treated with different concentrations of 4-Hydroxytamoxifen (2, 5, 10 and 15 μM) for 72 h. Results shown are mean ± SE of at least two independent experiments performed in triplicate. Asterisks denote p-values as follows: * p < 0.05; ** p < 0.005. The efficiency of SLC7A5 and SLC3A2 knockdown in (I) MCF7 cells and (K) MDA-MB-175-VII was confirmed by Western blotting.